Lonza, a partner to the pharmaceutical, biotech and nutraceutical markets, has completed a planned expansion of its bioconjugation facility in Visp, Switzerland.
The expansion includes two manufacturing suites and supporting infrastructure to support an extended customer portfolio, including companies entering clinical development. The investment enhances capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates.
Lonza also recently invested in expanding mammalian capacity, microbial development, drug product development and manufacturing, and HPAPI payload-linker manufacturing capacity in Visp. These continued investments into the Visp (CH) site aim to help customers navigate the risks of a complex bioconjugation supply chain. In addition to the two new manufacturing suites, the expansion also includes an increase in process and analytical development and quality control capacity to support future portfolio growth.
Stefan Egli, Vice President, Head of Bioconjugates, Lonza, said, “The opening of the new bioconjugate manufacturing suites in Visp (CH) reflects our dedication to continuously improving our offering and expertise in line with anticipated market and customer needs. Combined with our offerings across drug substance and drug product manufacturing in small molecules and biologics, our bioconjugation services can support projects from early phase through to late-stage and commercial programs.”
